...
首页> 外文期刊>Molecular pain >Paclitaxel induces acute pain via directly activating toll like receptor 4
【24h】

Paclitaxel induces acute pain via directly activating toll like receptor 4

机译:紫杉醇通过直接激活类似受体4的收费诱导急性疼痛

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Paclitaxel, a powerful anti-neoplastic drug, often causes pathological pain, which significantly reduces the quality of life in patients. Paclitaxel-induced pain includes pain that occurs immediately after paclitaxel treatment (paclitaxel-associated acute pain syndrome, P-APS) and pain that persists for weeks to years after cessation of paclitaxel treatment (paclitaxel induced chronic neuropathic pain). Mechanisms underlying P-APS remain unknown. In this study, we found that paclitaxel causes acute pain in rodents in a dose-dependent manner. The paclitaxel-induced acute pain occurs within 2 hrs after a single intravenous injection of paclitaxel. This is accompanied by low levels of paclitaxel penetrating into the cerebral spinal fluid and spinal dorsal horn. We demonstrated that an intrathecal injection of paclitaxel induces mechanical allodynia in a dose-dependent manner. Paclitaxel causes activation of toll like receptor 4 (TLR4) in the spinal dorsal horn and dorsal root ganglions. Through activating TLR4, paclitaxel increases glutamatergic synaptic activities and reduces glial glutamate transporter activities in the dorsal horn. Activations of TLR4 are necessary in the genesis of paclitaxel-induced acute pain. The cellular and molecular signaling pathways revealed in this study could provide rationales for the development of analgesics and management strategies for P-APS in patients.
机译:紫杉醇是一种强大的抗肿瘤药物,通常会引起病理性疼痛,从而大大降低患者的生活质量。紫杉醇引起的疼痛包括紫杉醇治疗后立即发生的疼痛(紫杉醇相关的急性疼痛综合征,P-APS)和停止紫杉醇治疗后持续数周至数年的疼痛(紫杉醇引起的慢性神经性疼痛)。 P-APS的基础机制仍然未知。在这项研究中,我们发现紫杉醇以剂量依赖性方式引起啮齿动物急性疼痛。紫杉醇单次静脉注射后2小时内,紫杉醇引起的急性疼痛发生。伴有少量紫杉醇渗透进入脑脊髓液和脊髓背角。我们证明鞘内注射紫杉醇以剂量依赖性方式诱导机械性异常性疼痛。紫杉醇可激活脊髓背角和背根神经节中的Toll样受体4(TLR4)。通过激活TLR4,紫杉醇增加了背角的谷氨酸能突触活性并减少了神经胶质谷氨酸转运蛋白的活性。在紫杉醇诱发的急性疼痛的发生中必须激活TLR4。这项研究中揭示的细胞和分子信号通路可以为患者使用P-APS的镇痛药和治疗策略提供理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号